3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
42
Small Cell Lung Carcinoma
19
Breast Neoplasms
16
Sarcoma
12
Lung Neoplasms
9
Esophageal Squamous Cell Carcinoma
7
Carcinoma, Hepatocellular
7
Thyroid Neoplasms
6
Stomach Neoplasms
6
Nasopharyngeal Carcinoma
6
Esophageal Neoplasms
6
Ovarian Neoplasms
5
NSCLC
5
Carcinoma
5
Triple Negative Breast Neoplasms
4
Pheochromocytoma
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Recurrence
3
Paraganglioma
3
Neoplasms
3
Glioma
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Biliary Tract Neoplasms
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Platinum-resistant Ovarian Cancer
2
Interventions
olaparib
1
niraparib
1
anlotinib
1
Diffusion
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adnexal Diseases
×
anlotinib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled